Compare Stocks

Asante Gold Corporation, a mineral exploration company, engages in the acquisition, exploration, and development of mineral resource properties in the Republic of Ghana. It holds 100% interest in the Fahiakoba concession situated in the Ashanti and Central regions in the Republic of Ghana; and 90% interest in the Bibiani gold mine located in the western region of Ghana. The company also has an option to acquire a 100% interest in the Betenase permit located in Ghana; 90% interest in the Kubi Mining lease located in southwest Ghana; and 100% interest in the Keyhole Gold project. Asante Gold Corporation was incorporated in 2011 and is based in Vancouver, Canada.

Helios Advantage Income Fund, Inc. (the Fund) is a diversified, closed-end management investment company. The Fund seeks a high level of current income. The Fund seeks capital growth as a secondary investment objective. It invests a majority of its total assets in below-investment-grade debt securities. The Fund also may invest in investment grade debt securities, up to 15% of its total assets in foreign debt and foreign equity securities, and up to 25% of its total assets in domestic equity securities, including common and preferred stocks. The Fund invests in a range of below-investment-grade debt securities, including corporate bonds, mortgage-backed and asset-backed securities, and municipal and foreign government obligations, as well as securities of companies in bankruptcy reorganization proceedings or otherwise in the process of debt restructuring. The Fund's investment advisor is Brookfield Investment Management Inc.

Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States. The Company operates primarily in the United States as two business segments: Par Pharmaceutical (Par), its generic products division, and Strativa Pharmaceuticals (Strativa), its branded products division. In February 17, 2012, the Company acquired Edict Pharmaceuticals Private Limited. On November 17, 2011, it acquired Anchen Incorporated and its subsidiary, Anchen Pharmaceuticals, Inc. In October 2011, it acquired rights to three products from Teva Pharmaceuticals in connection with Teva's acquisition of Cephalon. In September 2012, certain affiliates of TPG acquired the Company.